The Board of Directors considered, noted, and approved the following:

1. Approved the audited Financial Results along with the Auditors Report for the quarter and year ended March 31, 2026.

2. Noted the declaration with respect to an un-modified opinion on the Audited Financial Results pursuant to Regulation 33(3)(d) of the SEBI (LODR) Regulation, 2015.

The company is arranging to publish the Financial Results in newspapers in the format prescribed under Regulation 47 of the Listing Regulations.

Financial Results Highlights (Quarter Ended March 31, 2026)

  • Revenue from Operations: ₹1,019.47 lakh (₹10.19 crore)
  • Total Income: ₹1,019.72 lakh (₹10.20 crore)
  • Total Expenses: ₹10,879.60 lakh (₹108.80 crore)
  • Loss before tax: (₹682.40) lakh (₹-6.82 crore)
  • Tax Expense: (₹212.66) lakh (₹-2.13 crore) [Deferred Tax]
  • Net Loss for the quarter: (₹469.74) lakh (₹-4.70 crore)
  • Basic & Diluted EPS: (₹0.05)

Financial Results Highlights (Year Ended March 31, 2026)

  • Revenue from Operations: ₹14,175.23 lakh (₹141.75 crore)
  • Total Income: ₹14,257.62 lakh (₹142.58 crore)
  • Total Expenses: ₹15,099.00 lakh (₹150.99 crore)
  • Loss before tax: (₹841.38) lakh (₹-8.41 crore)
  • Tax Expense: (₹212.66) lakh (₹-2.13 crore) [Deferred Tax]
  • Net Loss for the year: (₹628.72) lakh (₹-6.29 crore)
  • Basic & Diluted EPS: (₹0.06)
  • Paid-up Equity Share Capital: ₹10,153.47 lakh (₹101.53 crore) [Face Value ₹1 each]

Comparative Figures (Year Ended March 31, 2025)

  • Net Profit for the year: ₹17.30 lakh (₹0.17 crore)
  • Basic & Diluted EPS: ₹0.00
  • Paid-up Equity Share Capital: ₹7,684.75 lakh (₹76.85 crore)

Key Notes to Financial Results

1. The Board of Directors did not recommend a dividend for the financial year 2025-26.

2. The company operates only in one segment: Pharmaceuticals & FMCG.

3. The company wrote off sundry debtors amounting to ₹9.70 crore during the year. The management assessed these balances as irrecoverable and charged the amount to the Statement of Profit and Loss.

4. No investor complaints were received during the quarter and year ended March 31, 2026.

5. There were no outstanding defaults on loans and debt securities.

Declaration

A separate declaration by Managing Director Rajnishkumar S. Singh (DIN: 07192704) was submitted, confirming the issuance of the audit report with an unmodified opinion, in compliance with Regulation 33(3)(d) and SEBI Circular No. CIR/CMD/56/2016.

Balance Sheet & Cash Flow Highlights (As of March 31, 2026)

  • Total Assets: ₹10,857.55 lakh (₹108.58 crore)
  • Total Equity: ₹10,256.22 lakh (₹102.56 crore)
  • Cash and cash equivalents: ₹959.08 lakh (₹9.59 crore)
  • Net cash used in operating activities: (₹865.14) lakh (₹-8.65 crore)
  • Net cash from financing activities: ₹2,471.61 lakh (₹24.72 crore), primarily from the issue of shares on a right basis.